Quantity of eligible individuals: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are categorised as owning moderate or reasonable ailment might have a serious